Side-by-side comparison of AI visibility scores, market position, and capabilities
Downers Grove IL diversified industrial manufacturer (NYSE: DOV) ~$7.7B 2024 revenue; data center liquid cooling, biopharma fluid path, clean energy fueling — niche market leader competing with IDEX and Parker Hannifin.
Dover Corporation is a Downers Grove, Illinois-based diversified industrial manufacturer — publicly traded on the New York Stock Exchange (NYSE: DOV) as an S&P 500 Industrials component — designing and manufacturing specialized equipment, components, and systems for biopharma, food and beverage, energy, digital printing, and clean energy markets through approximately 25,000 employees in 30+ countries. In fiscal year 2024, Dover reported revenue of approximately $7.7 billion with operating margins around 20%, demonstrating the consistent margin profile of Dover's portfolio of niche manufacturing businesses, each holding leading positions in served niches. A key leadership transition occurred at the CFO level: Brad Cerepak, Senior Vice President and CFO since May 2011, announced retirement effective January 31, 2025, with Christopher Woenker (previously CFO of the Engineered Products and Climate & Sustainability Technologies segments) succeeding. CEO Richard Tobin has positioned Dover around five operating segments: Engineered Products (vehicle service, industrial automation, aerospace), Clean Energy & Fueling (fuel and vehicle wash equipment), Imaging & Identification (digital printing systems, product identification), Pumps & Process Solutions (biopharma fluid path components, precision pumps, food and beverage process equipment), and Climate & Sustainability Technologies (heat exchangers, CO₂ refrigeration systems, data center thermal management). Dover's Climate & Sustainability Technologies segment has emerged as a high-growth platform through data center liquid cooling — the heat exchangers and cooling systems required for high-density AI server racks that air cooling cannot dissipate.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.